English | Español

Eli Lilly And Company
Patient Daily | May 25, 2023

Lilly ESG Report Highlights Progress Towards Sustainability Goals
Patient Daily | May 24, 2023

Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Patient Daily | May 22, 2023

Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
Patient Daily | May 9, 2023

Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana
Patient Daily | May 9, 2023

Lilly Declares Second-Quarter 2023 Dividend
Patient Daily | May 9, 2023

Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
Patient Daily | Apr 26, 2023

Lilly to Divest BAQSIMI to Amphastar
Patient Daily | Apr 26, 2023

Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities

Trending
+ Marketing
Patient Daily | Sep 17, 2025

Patients Come First spokesperson: Drug ads 'are putting lives at risk by encouraging people to abandon essential treatments'
+ Regulatory
Patient Daily | Sep 17, 2025

PhRMA’s Senior Director on 340B: 'State and federal investigations have shown 340B is often exploited for profit'
Patient Daily | Sep 19, 2025

ENT specialist on ongoing chronic sinus cases: ‘Some of it could be incomplete surgery’
+ Pharmaceuticals
Patient Daily | Sep 23, 2025

Wall Street Journal editorial board alleges hospitals misuse 340B program